Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Tharmalingam, Nagendran ^a   Port, Jenna ^a   Castillo, Dawilmer ^a   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHELMINTIC AGENT; ANTIINFECTIVE AGENT; CLOSANTEL; NICLOSAMIDE; OMEPRAZOLE; OXYCLOZANIDE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RAFOXANIDE; SALICYLANILIDE DERIVATIVE;

DRUG EFFECT; DRUG POTENTIATION; DRUG REPOSITIONING; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ANTHELMINTICS; ANTI-INFECTIVE AGENTS; DRUG REPOSITIONING; DRUG SYNERGISM; HELICOBACTER PYLORI; MICROBIAL SENSITIVITY TESTS; NICLOSAMIDE; OMEPRAZOLE; OXYCLOZANIDE; PANTOPRAZOLE; PROTON PUMP INHIBITORS; RAFOXANIDE; SALICYLANILIDES;

EID: 85042719501     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-22037-x     Document Type: Article

References (68)

1. Thung, I. et al. The global emergence of Helicobacter pylori antibiotic resistance. Alimentary pharmacology & therapeutics 43, 514-533 (2016).
2. Hagymási, K. & Tulassay, Z. Helicobacter pylori infection: new pathogenetic and clinical aspects. World journal of gastroenterology: WJG 20, 6386 (2014).
3. Graham, D. Y. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 148, 719-731. e713 (2015).
4. Lin, Y.-L., Chiang, J.-K., Lin, S.-M. & Tseng, C.-E. Helicobacter pylori infection concomitant with metabolic syndrome further increase risk of colorectal adenomas. World Journal of Gastroenterology: WJG 16, 3841 (2010).
5. Wu, Q., Yang, Z. P., Xu, P., Gao, L. C. & Fan, D. M. Association between helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. Colorectal Disease 15 (2013).
6. Weyermann, M., Rothenbacher, D. & Brenner, H. Acquisition of Helicobacter pylori infection in early childhood: independent contributions of infected mothers, fathers, and siblings. The American journal of gastroenterology 104, 182 (2009).
7. Nguyen, T. N., Barkun, A. N. & Fallone, C. A. Host determinants of Helicobacter pylori infection and its clinical outcome. Helicobacter 4, 185-197 (1999).
8. Peek, R. M. Jr. & Blaser, M. J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nature reviews. Cancer 2, 28 (2002).
9. Eusebi, L. H., Zagari, R. M. & Bazzoli, F. Epidemiology of Helicobacter pylori infection. Helicobacter 19, 1-5 (2014).
10. Romano, M. & Cuomo, A. Eradication of Helicobacter pylori: a clinical update. Medscape General Medicine 6, 19 (2004).
11. Shiota, S., Reddy, R., Alsarraj, A., El-Serag, H. B. & Graham, D. Y. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clinical Gastroenterology and Hepatology 13, 1616-1624 (2015).
12. Rodvold, K. A. & McConeghy, K. W. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clinical infectious diseases 58, S20-S27 (2014).
13. Rajamuthiah, R. et al. Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus. PLoS One 10, e0124595, https://doi.org/10.1371/journal.pone.0124595 (2015).
14. Rajamuthiah, R. et al. Whole animal automated platform for drug discovery against multi-drug resistant Staphylococcus aureus. PLoS One 9, e89189, https://doi.org/10.1371/journal.pone.0089189 (2014).
15. Gooyit, M. & Janda, K. D. Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile. Scientific reports 6, 33642 (2016).
16. Imperi, F. et al. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrobial agents and chemotherapy 57, 996-1005 (2013).
17. Hall, A. Anthelmintics: drugs for treating worms. Africa health 20, 4-6 (1998).
18. Kappagoda, S., Singh, U. & Blackburn, B. G. In Mayo Clinic Proceedings. 561-583 (Elsevier) (2011).
19. Craig, C. R. & Stitzel, R. E. Modern Pharmacology with Clinical Applications. (Lippincott Williams & Wilkins, 2004).
20. Organization, W. H. The selection and use of essential medicines: report of the WHO Expert Committee, 2007:(including the 15th model list of essential medicines). (2007).
21. Jayamani, E. et al. Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds. Antimicrobial agents and chemotherapy 61, e00310-00317 (2017).
22. De Francesco, V. et al. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. World journal of gastrointestinal pathophysiology 2, 35 (2011).
23. Torella, J. P., Chait, R. & Kishony, R. Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol 6, e1000796 (2010).
24. Odds, F. C. (Br Soc Antimicrob Chemo, 2003).
25. Gatta, L. et al. Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. Journal of Antimicrobial Chemotherapy 51, 439-442 (2003).
26. Adamek, R. J., Szymanski, C. & Pfaffenbach, B. Pantoprazole suppresses Helicobacter pylori without affecting cure. Helicobacter 4, 266-271 (1999).
27. Sugiyama, T. In Proton Pump Inhibitors: A Balanced View Vol. 32, 59-67 (Karger Publishers, 2013).
28. Odenbreit, S. Adherence properties of Helicobacter pylori: impact on pathogenesis and adaptation to the host. International journal of medical microbiology 295, 317-324 (2005).
29. Dubois, A. & Borén, T. Helicobacter pylori is invasive and it may be a facultative intracellular organism. Cellular microbiology 9, 1108-1116 (2007).
30. Tan, S., Tompkins, L. S. & Amieva, M. R. Helicobacter pylori usurps cell polarity to turn the cell surface into a replicative niche. PLoS pathogens 5, e1000407 (2009).
31. Mirshahi, F., Fowler, G., Patel, A. & Shaw, G. Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity. Journal of clinical pathology 51, 220-224 (1998).
32. Yamaoka, Y. et al. Induction of various cytokines and development of severe mucosal inflammation by cagA gene positive Helicobacter pylori strains. Gut 41, 442-451 (1997).
33. Zhang, Q. et al. Association of antral mucosal levels of interleukin 8 and reactive oxygen radicals in patients infected with Helicobacter pylori. Clinical Science 92, 69-73 (1997).
34. Crabtree, J. E. & Lindley, I. Mucosal interleukin-8 and Helicobacter pylori-associated gastroduodenal disease. European journal of gastroenterology & hepatology 6, S33-38 (1994).
35. Cyphert, E. L., Wallat, J. D., Pokorski, J. K. & von Recum, H. A. Erythromycin Modification That Improves Its Acidic Stability while Optimizing It for Local Drug Delivery. Antibiotics 6, 11 (2017).
36. Daarmaillac, V., Bouchard, S., Lamouliatte, H. & Mégraud, F. In Gastroenterology. A78-A78 (Wb Saunders Co Independence Square West Curtis Center, Ste 300, Philadelphia, Pa 19106-3399).
37. Baudoux, P. et al. Combined effect of pH and concentration on the activities of gentamicin and oxacillin against Staphylococcus aureus in pharmacodynamic models of extracellular and intracellular infections. J Antimicrob Chemother 59, 246-253, https://doi.org/10.1093/jac/dkl489 (2007).
38. Falagas, M. E., McDermott, L. & Snydman, D. R. Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group. Antimicrob Agents Chemother 41, 2047-2049 (1997).
39. Lemaire, S., Van Bambeke, F., Mingeot-Leclercq, M. P., Glupczynski, Y. & Tulkens, P. M. Role of acidic pH in the susceptibility of intraphagocytic methicillin-resistant Staphylococcus aureus strains to meropenem and cloxacillin. Antimicrob Agents Chemother 51, 1627-1632, https://doi.org/10.1128/AAC.01192-06 (2007).
40. Ghotaslou, R., Leylabadlo, H. E. & Asl, Y. M. Prevalence of antibiotic resistance in Helicobacter pylori: A recent literature review. World journal of methodology 5, 164 (2015).
41. Matsumoto, H. et al. Helicobacter pylori eradication with proton pump inhibitors or potassium-competitive acid blockers: the effect of clarithromycin resistance. Digestive diseases and sciences 61, 3215-3220 (2016).
42. Ottemann, K. M. & Lowenthal, A. C. Helicobacter pylori uses motility for initial colonization and to attain robust infection. Infection and immunity 70, 1984-1990 (2002).
43. Zhang, L. et al. Critical role of antimicrobial peptide cathelicidin for controlling helicobacter pylori survival and infection. The Journal of Immunology 196, 1799-1809 (2016).
44. Galmiche, A. & Rassow, J. Targeting of Helicobacter pylori VacA to mitochondria. Gut microbes 1, 392-395 (2010).
45. Seto, K., Hayashi-Kuwabara, Y., Yoneta, T., Suda, H. & Tamaki, H. Vacuolation induced by cytotoxin from Helicobacter pylori is mediated by the EGF receptor in HeLa cells. FEBS letters 431, 347-350 (1998).
46. Hurdle, J. G., O'neill, A. J., Chopra, I. & Lee, R. E. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nature Reviews Microbiology 9, 62-75 (2011).
47. Zhao, J., He, Q., Gong, Z., Chen, S. & Cui, L. Niclosamide suppresses renal cell carcinoma by inhibiting Wnt/β-catenin and inducing mitochondrial dysfunctions. Springer Plus 5, 1436 (2016).
48. Farha, M. A., Verschoor, C. P., Bowdish, D. & Brown, E. D. Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. Chemistry & biology 20, 1168-1178 (2013).
49. Tharmalingam, N. et al. Activity of a novel protonophore against methicillin-resistant Staphylococcus aureus. Future Med Chem In press (2017).
50. Arundel, J. et al. Chemotherapy of gastrointestinal helminths. Vol. 77 (Springer Science & Business Media, 2012).
51. Prevention, U. S. Niclosamide EPA (1999).
52. Giannouli, M. et al. Use of larvae of the wax moth Galleria mellonella as an in vivo model to study the virulence of Helicobacter pylori. BMC microbiology 14, 228 (2014).
53. Wikler, M. A. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. (Clinical and Laboratory Standards Institute, 2006).
54. Tharmalingam, N. et al. Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen Microbial Drug Resistance (Accepted) (2018).
55. Gwisai, T. et al. Repurposing niclosamide as a versatile antimicrobial surface coating against device-associated, hospital-acquired bacterial infections. Biomedical Materials (2017).
56. Zheng, Z. et al. Synergistic efficacy of Aedes aegypti antimicrobial peptide cecropin A2 and tetracycline against Pseudomonas aeruginosa. Antimicrob Agents Chemother 61 (2017).
57. Schmitt, D. M. et al. The use of resazurin as a novel antimicrobial agent against Francisella tularensis. Front Cell Infect Microbiol 3, 93, https://doi.org/10.3389/fcimb.2013.00093 (2013).
58. Tharmalingam, N. et al. Piperine treatment suppresses Helicobacter pylori toxin entry in to gastric epithelium and minimizes β-catenin mediated oncogenesis and IL-8 secretion in vitro. American journal of translational research 8, 885 (2016).
59. Lee, M. H. et al. Menadione induces G2/M arrest in gastric cancer cells by down-regulation of CDC25C and proteasome mediated degradation of CDK1 and cyclin B1. American journal of translational research 8, 5246 (2016).
60. De Kimpe, S. J., Kengatharan, M., Thiemermann, C. & Vane, J. R. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proceedings of the National Academy of Sciences 92, 10359-10363 (1995).
61. Zheng, Z. et al. Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus. Future Medicinal Chemistry Accepted (2017).
62. Dalhoff, A. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clinical infectious diseases 32, S16-S22 (2001).
63. Suerbaum, S., Josenhans, C. & Labigne, A. Cloning and genetic characterization of the Helicobacter pylori and Helicobacter mustelae flaB flagellin genes and construction of H. pylori flaA-and flaB-negative mutants by electroporation-mediated allelic exchange. Journal of bacteriology 175, 3278-3288 (1993).
64. Tharmalingam, N. et al. Inhibitory effect of piperine on Helicobacter pylori growth and adhesion to gastric adenocarcinoma cells. Infectious agents and cancer 9, 43 (2014).
65. Kim, W. et al. Identification of an Antimicrobial Agent Effective against Methicillin-Resistant Staphylococcus aureus Persisters Using a Fluorescence-Based Screening Strategy. PLoS One 10, e0127640, https://doi.org/10.1371/journal.pone.0127640 (2015).
66. Scott, D. R. et al. Expression of the Helicobacter pylori ureI gene is required for acidic pH activation of cytoplasmic urease. Infection and immunity 68, 470-477 (2000).
67. Kwon, B. et al. Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis. Hum Mol Genet 23, 3681-3694, https://doi.org/10.1093/hmg/ddu077 (2014).
68. Isnansetyo, A. & Kamei, Y. MC21-A, a bactericidal antibiotic produced by a new marine bacterium, Pseudoalteromonas phenolica sp. nov. O-BC30(T), against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 47, 480-488 (2003).